

EMA/28287/2018

European Medicines Agency decision

P/0020/2018

of 30 January 2018

on the refusal of a modification of an agreed paediatric investigation plan for gadolinium, [α3,α6,α9-tris[3-[(2,3-dihydroxypropyl)amino]-3-oxopropyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-κN3,κN6,κN9,κN15,κO3,κO6,κO9]-(P03277), (EMA-001949-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0020/2018

of 30 January 2018

on the refusal of a modification of an agreed paediatric investigation plan for gadolinium, [α 3, α 6, α 9-tris[3-[(2,3-dihydroxypropyl)amino]-3-oxopropyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)- κ N3, κ N6, κ N9, κ N15, κ O3, κ O6, κ O9]- (P03277), (EMA-001949-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0076/2017 issued on 17 March 2017,

Having regard to the application submitted by GUERBET on 21 September 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 December 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the refusal of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the refusal of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for gadolinium, [α 3, α 6, α 9-tris[3-[(2,3-dihydroxypropyl)amino]-3-oxopropyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)- κ N3, κ N6, κ N9, κ N15, κ O3, κ O6, κ O9]-(P03277), solution for injection, intravenous use, including changes to the deferral, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, are hereby refused.

Article 2

This decision is addressed to GUERBET, BP 57400 Roissy CDG Cedex, 95943 - ROISSY CDG, France.

EMA/PDCO/647863/2017
London, 15 December 2017

Opinion of the Paediatric Committee on the refusal of a modification of an agreed Paediatric Investigation Plan

EMA-001949-PIP01-16-M01

Active substance(s):

Gadolinium, [α3,α6,α9-tris[3-[(2,3-dihydroxypropyl)amino]-3-oxopropyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-κN3,κN6,κN9,κN15,κO3,κO6,κO9]-(P03277)

Condition(s):

Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

GUERBET

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, GUERBET submitted to the European Medicines Agency on 21 September 2017 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0076/2017 issued on 17 March 2017.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 17 October 2017.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to refuse the changes proposed by the applicant regarding the paediatric investigation plan and the deferral.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan remain unchanged and are set out in the Annex I.
3. The scientific conclusions and the grounds for refusal are set out in the summary report appended to this opinion.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes

2.1.1. Indication(s) targeted by the PIP

MRI in brain (intracranial), spine and associated tissues to detect and visualise areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate dosage form for parenteral use
Non-clinical studies	2	Study 2 Dose-range finding juvenile toxicity study in rats Study 3 Definitive juvenile toxicity study in rats
Clinical studies	2	Study 4 Non-comparative pharmacokinetics, efficacy and safety study in children from 2 to less than 18 years of age presenting central nervous system (CNS) lesions (intracranial, spine and associated tissues), who are scheduled to undergo routine contrast-enhanced MRI of CNS Study 5 Non-comparative pharmacokinetic, efficacy and safety study in children from birth to less than 2 years of age scheduled to undergo routine contrast-enhanced MRI

		of any body region, including a minimum of 50% children presenting CNS lesions
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By May 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes